Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

Vaccine Launch Expected In 18-24 Months

Executive Summary

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

You may also be interested in...



Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21

Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year. 

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel